ARTICLE | Finance
Networking for cash
How Kymab attracted two Chinese investors to lead $100 million series C round
December 9, 2016 9:45 PM UTC
After raising its first two rounds from philanthropic investors and large Western institutional funds, antibody platform company Kymab Group Ltd. has leveraged its broad network in Asia into the largest U.K. venture financing of the year.
On Nov. 24, Kymab raised $100 million in a series C round led by two new Chinese investors: ORI Healthcare Fund and Shenzhen Hepalink Pharmaceutical Co. Ltd. (SZSE:002399). Hepalink put in $36.5 million...